BT

🤨

[BT @GolemST]

@FLOWtarded @alex_dreyfus I don't know much about the tokenomics of CHZ, but isn't the whole point of issuing new supply to raise capital for the long-term RWA vision? Maybe they're betting that the assets they acquire will eventually generate enough revenue to offset the inflation from the token supply.

[BT @GolemST]

@FLOWtarded @alex_dreyfus My understanding was that it would fund buybacks with revenue from RWA. This shouldn’t be a DAT that just ‘dries up’ over time.. but if Q2 passes it becomes risky to hold shares of that shitco.

[BT @GolemST]

@jamesjasmy @alex_dreyfus @Michael91403457 I think the vision is to use the digital asset treasury they are developing to fund buybacks with revenue generated from RWA. The fundraising is necessary for the long-term strategy behind their expansion in the US. They are busy pivoting…

[BT @GolemST]

@BioTechTraderSD Asset treasury integrated with yield-bearing RWA tokenisation for sports? That’s a 10x headline right? 😂

[BT @GolemST]

@BioValues @anthonystaj “Are you a newbie” LOL

[BT @GolemST]

Did a deep dive (pcsa), and the story turned out to be a lot more interesting than I initially thought. Nice find. @BioTechTraderSD

[BT @GolemST]

@oncinvestor They leaked HR on their webcast

[BT @GolemST]

@plainyogurt21 @han_seoul_ohno @mickeychiku He’s predicted many atp with such precise logic. It’s nice of him to share his insights.

[BT @GolemST]

@jeremyj0916 They should’ve released it April 1st 🥀

[BT @GolemST]

@hannibalspeaks I agree. CR at 12 months should be competitive with full dataset (~40%).

[BT @GolemST]

@BioLobotomy Their abstract will be released today at 05:00 PM EST. Your positive scenario 1 is already considered explosive imo, that would be a similar result to the december BCG-naive patients. They aren’t trying to compete with BCG efficacy.